ReviewRheumatic diseases clinics of North America2008
The heart in scleroderma.
Review in Rheumatic diseases clinics of North America, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 2 syntheses or guidelines pooled it, 168 citations in OpenAlex.
- Safety of pericardiocentesis in pulmonary arterial hypertension: a systematic review.Frontiers in cardiovascular medicine · 2025Pooled it
- Repolarization in systemic sclerosis: a meta-analysis.Clinical rheumatology · 2022Pooled it
- Transcatheter Aortic Valve Replacement in Systemic Sclerosis: A Case Series and Review of Short- and Long-Term Outcomes.Mediterranean journal of rheumatology · 2026Article
- Multimodality imaging approach in cardiac asymptomatic subjects with systemic sclerosis followed at a tertiary center.Frontiers in cardiovascular medicine · 2026Article
- Leveraging Artificial Intelligence for the Diagnosis of Systemic Sclerosis Associated Pulmonary Arterial Hypertension: Opportunities, Challenges, and Future Perspectives.Advances in respiratory medicine · 2025Review
- Predictive Value of Classical and Emerging Autoantibodies for Cardiac Dysfunction in Systemic Sclerosis: Systematic Review.Journal of clinical medicine · 2025Review
- Light Chain (AL) Amyloidosis Masquerading as Scleroderma: A Diagnostic Challenge.Journal of hematology · 2025Article
- Exploring the Impact of Fragmented QRS on Ejection Fraction and Other Echocardiographic Parameters in Systemic Sclerosis Patients: A Retrospective Cohort Study.Research in heart yield and translational medicine · 2025Article
- Cardiac magnetic resonance in systemic sclerosis: imaging features and potential prognostic implications. A literature review.Frontiers in medicine · 2025Review
- A multi-biomarker approach to risk stratification and detection of early cardiac disease in systemic sclerosis.PloS one · 2025Observational
- Non-Invasive Cardiac and Vascular Monitoring in Systemic Sclerosis: Impact of Therapy on Subclinical Dysfunction.Medicina (Kaunas, Lithuania) · 2024Article
- Neurological, cardiac, musculoskeletal, and renal manifestations of scleroderma along with insights into its genetics, pathophysiology, diagnostic, and therapeutic updates.Health science reports · 2024Article
- Rapidly Progressive Primary Scleroderma Cardiomyopathy in a Young Adult Characterized by Multimodality Imaging.CASE (Philadelphia, Pa.) · 2023Article
- Article
- Purtscher-like Retinopathy in a Patient with Systemic Sclerosis: A Case Report and Narrative Review.Biomedicines · 2023Article
- Association between systemic sclerosis and left ventricle dysfunction: Findings from observational studies.Heliyon · 2023Article
- Article
- Clinical features of pulmonary arterial hypertension associated with systemic sclerosis.Frontiers in medicine · 2023Review
- Successful Treatment of Systemic Sclerosis-related Pericarditis with Mycophenolate Mofetil and Low-dose Prednisolone.Internal medicine (Tokyo, Japan) · 2022Article
- A case of systemic sclerosis with worsened subclinical left ventricular systolic dysfunction after pacemaker implantation.Journal of cardiology cases · 2022Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The heart is one of the major organs involved in scleroderma, the involvement of which can be manifested by myocardial disease, conduction system abnormalities, arrhythmias, or pericardial disease. Additionally, scleroderma renal crisis and pulmonary hypertension lead to significant cardiac dysfunction secondary to damage in the kidney and lung. This article summarizes the types and mechanism of abnormalities in the heart in scleroderma. The concept of cardiac dysfunction in scleroderma and other rheumatologic conditions has received new interest with the advent of newer noninvasive imaging techniques, as well as the interest in detecting subclinical disease. With this increased interest in cardiac manifestations in scleroderma comes the realization that long-term studies are needed to better assess the appropriate screening and treatment in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.